<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882191</url>
  </required_header>
  <id_info>
    <org_study_id>CMDOC-0022</org_study_id>
    <nct_id>NCT02882191</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of LevoCept</brief_title>
  <official_title>Evaluation of the Effectiveness, Safety and Tolerability of LevoCept (Levonorgestrel-Releasing Intrauterine System) for Long-Acting Reversible Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraMed LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ContraMed LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to
      support commencing a Phase III Clinical Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Prospective, multi-center, single-arm, open-label, Phase II clinical study

      250 subjects will be enrolled at unto 14 centers in the US.

      Study Population: Pre-menopausal women ages 18 - 40, at risk for pregnancy, who are
      interested in using only this intrauterine contraceptive for birth control will be eligible
      for this study. Subjects must provide written informed consent and meet the study subject
      selection criteria without any exclusions as outlined in the Clinical Investigation Plan
      (CIP).

      Primary Effectiveness Outcome:

      The primary outcome measure is effectiveness, evaluated as the absence of pregnancy at 12
      months.

      Safety and other outcome measures include:

      Study Device Placement:

        -  Ease of placement

        -  Placement success

      Safety:

        -  Serious Adverse Events

        -  Adverse Events

      Tolerability:

        -  Bleeding and spotting patterns

        -  Discontinuation rate and reasons for discontinuation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absence of pregnancy at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>LevoCept IUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LevoCept IUD placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LevoCept</intervention_name>
    <description>placement of LevoCept IUD</description>
    <arm_group_label>LevoCept IUD</arm_group_label>
    <other_name>Levonorgestrel-Releasing Intrauterine System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18-40 years of age at the time of study initiation; 1.1 Enrollment will be
             targeted for 225 subjects aged 18-35 (for safety and effectiveness analyses) and an
             additional 25 subjects aged 36-40 (for safety only) (note: all subjects will be
             included in the analysis for device placement and tolerability);

          2. Pre-menopausal, as determined by regular menstrual cycle (28 ± 7 days) for the last 3
             months; 2.1 Based on patient history, when not on hormonal contraceptives;

          3. Sexually active with a male partner who has not had a vasectomy;

          4. Reasonably expected to have to coitus at least once monthly during the study period.

          5. In a mutually monogamous relationship of at least 3-6 months duration;

          6. Seeking to avoid pregnancy for the next 12 months;

          7. Willing to use the study device as the sole form of contraception;

          8. Willing to accept a risk of pregnancy;

          9. Normal PAP or ASC-US with negative high risk HPV test result within the appropriate
             screen timeframe, unless considered at risk;

         10. Able and willing to comply with all study tests, procedures, assessment tools and
             follow-up; and

         11. Able and willing to provide and document informed consent and Authorization for
             Release of Protected Health Information (PHI).

        Exclusion Criteria:

          1. Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse
             earlier in current cycle

          2. Subject who anticipates separation from her partner for more than 1 cycle within the
             next 12 months;

          3. A previously inserted IUD that has not been removed by the time LevoCept is placed;

          4. History of previous IUD complications, such as perforation, expulsion, infection
             (pelvic inflammatory disease) or pregnancy with IUD in place.;

          5. Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months;
             5.1 Must have had 2 normal menstrual cycles since the last injection;

          6. Planned use of any non-contraceptive estrogen, progesterone or testosterone any time
             during the 12 months of study participation;

          7. Postpartum, prior to a minimum of 6 weeks or complete uterine involution;

          8. Exclusively breastfeeding before return of menses; Lactating women will be excluded
             unless they have had have had two normal menstrual periods prior to enrollment.

             8.1 Must have had 2 normal spontaneous menstrual cycles since delivery

          9. Unexplained abnormal uterine bleeding (suspicious for serious condition), before
             evaluation; Immediately post-septic abortion or puerperal sepsis;

         10. Severely heavy or painful menstrual bleeding;

         11. Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically
             significant abnormal pap smear requiring evaluation or treatment.

         12. Any history of gestational trophoblastic disease with or without detectable elevated
             ß-hCG levels, or related malignant disease without an intervening normal pregnancy;

         13. Known anatomical abnormalities of the uterine cavity that may complicate IUD
             placement, such as:

             13.1 Submucosal uterine leiomyoma 13.2 Asherman's syndrome 13.3 Pedunculated polyps
             13.4 Bicornuate uterus 13.5 Didelphus or uterine septa

         14. Known anatomical abnormalities of the cervix such as severe cervical stenosis, prior
             trachelectomy or extensive conization that, in the opinion of the investigator would
             prevent cervical dilation and study device placement;

         15. Current or recent (within the last 3 months) pelvic infection (cervix, endometrium,
             or fallopian tubes), or mucopurulent cervicitis;

         16. High risk for STDs (e.g., multiple sexual partners);

         17. Known or suspected HIV infection or clinical AIDS;

         18. Known intolerance or allergy to any component of the LevoCept system; including
             nickel, silicone or tantalum;

         19. Currently participating or planning future participation in a research study of an
             investigational drug or device during the course of this investigational study;

         20. Subject had LevoCept placed previously or had 2 attempts at placement;

         21. Known or suspected alcohol or drug abuse within 12 months prior to the screening
             visit;

         22. Any general health or behavioral condition that, in the opinion of the Investigator,
             could represent an increased risk for the subject or would render the subject less
             likely to provide the needed study information.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Turok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin P Peters, PHD, MSC</last_name>
    <email>Kpeters@contramed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Essential Access Health-Berkeley</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fung Lam, MD</last_name>
      <phone>510-647-0630</phone>
      <email>lamf@cfhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Essential Access Health-Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Nelson, MD</last_name>
      <phone>888-702-0808</phone>
      <email>nelsona@essentialaccess.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Health System Department of Obstetrics and Gynecology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Creinin, MD</last_name>
      <phone>916-734-6963</phone>
      <email>MDCreinin@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Department of Obstetrics &amp; Gyncology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Teal, MD</last_name>
      <phone>303-724-2038</phone>
      <email>Stephanie.teal@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Data, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine Gynecology/Obstetrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Cwiak, MD</last_name>
      <phone>404-778-1378</phone>
      <email>ccwiak@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bliss Kaneshiro, MD</last_name>
      <phone>808-983-6000</phone>
      <email>blissk@hawaii.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Westhoff, MD</last_name>
      <phone>212-305-4805</phone>
      <email>clw3@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Thomas, MD</last_name>
      <phone>513-584-4100</phone>
      <email>Michael.Thomas@uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Isley, MD</last_name>
      <phone>614-293-3069</phone>
      <email>michelle.isley@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Jensen, MD</last_name>
      <phone>503-494-3127</phone>
      <email>jensenje@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Schreiber, MD</last_name>
      <phone>215-615-6531</phone>
      <email>cschreiber@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Andruczyk, DO</last_name>
      <phone>215-676-6696</phone>
      <email>Eugene@phillyresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Eubank, MD</last_name>
      <phone>361-906-9178</phone>
      <email>eubank@araresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Healthcare Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Gawron, MD</last_name>
      <phone>312-560-6162</phone>
      <email>ori.gawron@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Women's: Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Kroll, MD</last_name>
      <phone>206-522-3330</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>August 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
